• 1
    Durand B, Saunders M, Gaudon C, Roy B, Losson R, Chambon P 1994 Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: Presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J 13:53705382.
  • 2
    Masuyama H, Brownfield CM, St-Arnaud R, MacDonald PN 1997 Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol Endocrinol 11:15071517.
  • 3
    Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375:377382.
  • 4
    Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378:681689.
  • 5
    Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378:690697.
  • 6
    Lupisella JA, Driscoll JE, Metzler WJ, Reczek PR 1995 The ligand binding domain of the human retinoic acid receptor gamma is predominantly alpha-helical with a Trp residue in the ligand binding site. J Biol Chem 270:2488424890.
  • 7
    Strugnell SA, Hill JJ, McCaslin DR, Wiefling BA, Royer CA, DeLuca HF 1999 Bacterial expression and characterization of the ligand-binding domain of the vitamin D receptor. Arch Biochem Biophys 364:4252.
  • 8
    Cheng L, Norris AW, Tate BF, Rosenberger M, Grippo JF, Li E 1994 Characterization of the ligand binding domain of human retinoid X receptor alpha expressed in Escherichia coli. J Biol Chem 269:1866218667.
  • 9
    Jin CH, Kerner SA, Hong MH, Pike JW 1996 Transcriptional activation and dimerization functions in the human vitamin D receptor. Mol Endocrinol 10:945957.
  • 10
    Green S, Isseman I, Scheer E 1988 A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 16:369.
  • 11
    Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR 1989 Site directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:5159.
  • 12
    Solomon C, Sebag M, White JH, Rhim J, Kremer R 1998 Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes. J Biol Chem 273:1757317578.
  • 13
    Sebag M, Henderson J, Rhim J, Kremer R 1992 Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. J Biol Chem 267:1216212167.
  • 14
    Ferrara J, McCuaig KA, Hendy GN, Uskokovic M, White JH 1994 Highly potent transcriptional activation by 16-ene derivatives of 1,25-dihydroxyvitamin D3. Lack of modulation by 9-cis-retinoic acid of response to 1,25-dihydroxyvitamin D3 or its derivatives. J Biol Chem 269:29712981.
  • 15
    Banville D, Boie Y 1990 Retroviral long terminal repeat is the promoter of the gene encoding the tumor associated calcium-binding protein oncomodulin in the rat. J Mol Biol 207:481490.
  • 16
    Nakajima S, Hsieh J, Jurutka P, Galligan M, Haussler C, Whitfield G, Haussler M 1996 Examination of the potential functional role of conserved cysteine residues in the hormone binding domain of the human 1,25-dihydroxyvitamin D3 receptor. J Biol Chem 271:51435149.
  • 17
    Rut AR, Hewison M, Kristjansson K, Luisi B, Hughes MR, O'Riordan JLH 1994 Two mutations causing vitamin D resistant rickets: Modeling on the basis of steroid hormone receptor DNA-binding domain crystal structures. Clin Endocrinol (Oxf) 41:581590.
  • 18
    Kristjansson K, Rut AR, Hewison M, O'Riordan JLH, Hughes MR 1993 Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25-dihydroxyvitamin D3. J Clin Invest 92:1216.
  • 19
    Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R, Feldman D 1997 Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular responsiveness. J Clin Invest 99:297304.
  • 20
    Whitfield GK, Selznick SH, Haussler CA, Hsieh J-C, Galligan MA, Jurutka PW, Thompson PD, Lee SM, Zerwekh JE, Haussler MR 1996 Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: Point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol Endocrinol 10:16171631.